Biotech Celgene (CELG) received a double dose of good news Tuesday as its drug Abraxane won a key approval in Europe, and partner Epizyme (EPZM) produced positive results on its leukemia drug. In early trading, Celgene stock was up 2%, near 165, while Epizyme’s vaulted 68% in the stock market today. The European Commission approved Abraxane combined with gemcitabine (better known as Eli Lilly’s (LLY) Gemzar) as a first-line treatment for
Shares of biotechs Celgene (CELG) and Infinity Pharmaceuticals (INFI) were both up in the stock market today on strong clinical data on their blood-cancer drugs presented at the American Society of Hematology conference over the weekend. Celgene reported details from its MM020 trial of Revlimid, which is already a blockbuster approved for treating relapsed multiple myeloma. The trial is studying the risk/benefit profile of Revlimid for long-term
From Saturday through Tuesday, reps from drugmakers around the world will be gathering in New Orleans to present data on their blood-disease drugs at the American Society of Hematology conference. Among them are two top-rated big-cap biotechs, and though the abstracts are already out, the details of their reports have the potential to move stocks. Celgene (CELG) on Sunday afternoon will offer long-awaited data from its MM020 trial, which is meant